Literature DB >> 3133143

Lymphocytes from patients with primary biliary cirrhosis spontaneously secrete high levels of IgG3 in culture.

P Bird1, J E Calvert, H Mitchison, N R Ling, M Bassendine, O F James.   

Abstract

The origin of the raised serum IgG3 in primary biliary cirrhosis has been examined. Blood lymphocytes from patients with PBC and from age- and sex-matched controls were cultured, and the culture supernatants were assayed for IgG and IgG3. Lymphocytes from PBC patients spontaneously synthesized a higher percentage IgG3/total IgG than did control lymphocytes, as determined by ELISA. The increased synthesis of IgG3 in culture correlated with serum IgG3 in the patients. This strongly suggests that the raised serum IgG3 in these patients is due to increased synthesis of this isotype. Following PWM stimulation, the proportion of IgG3/IgG synthesized by normal (and most PBC) lymphocytes increased and the difference in IgG3 synthesized by PBC and control lymphocytes became less marked. The kappa/lambda light chain ratio of the IgG3 was assayed by ELISA but no evidence was found for clonally restricted synthesis of IgG3 by PBC blood lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133143      PMCID: PMC1541685     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  In vitro anti-mitochondrial antibody synthesis in patients with primary biliary cirrhosis.

Authors:  R E Rocklin; N R Maxwell; L Thistle; M M Kaplan
Journal:  Clin Immunol Immunopathol       Date:  1986-01

2.  IgG subclasses in viral infections.

Authors:  F Skvaril
Journal:  Monogr Allergy       Date:  1986

3.  Quantitation of immunoglobulin classes and subclasses in anti-Rh (D) antibodies.

Authors:  P S Mattila; I J Seppälä; J Eklund; O Mäkelä
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144

4.  Subclass distribution of IgG autoantibodies in bullous pemphigoid.

Authors:  P Bird; P S Friedmann; N Ling; A G Bird; R A Thompson
Journal:  J Invest Dermatol       Date:  1986-01       Impact factor: 8.551

Review 5.  IgG subclass changes in response to vaccination.

Authors:  L Hammarström; C I Smith
Journal:  Monogr Allergy       Date:  1986

6.  IgG subclasses of anti-tetanus toxoid antibodies in adult and newborn normal subjects and in patients with systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity.

Authors:  R L Rubin; F L Tang; A H Lucas; H L Spiegelberg; E M Tan
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

7.  IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity.

Authors:  R L Rubin; F L Tang; E K Chan; K M Pollard; G Tsay; E M Tan
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

8.  Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?

Authors:  H C Mitchison; M F Bassendine; A Hendrick; M K Bennett; G Bird; A J Watson; O F James
Journal:  Hepatology       Date:  1986 Nov-Dec       Impact factor: 17.425

9.  Circulating activated B cells in primary biliary cirrhosis.

Authors:  S P James; E A Jones; J H Hoofnagle; W Strober
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

10.  The in vitro production of antibodies to mitochondrial antigens by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.

Authors:  M I Avigan; G Adamson; J H Hoofnagle; E A Jones
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

View more
  2 in total

1.  Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.

Authors:  Nikita Joshi; Anna K Kopec; Holly Cline-Fedewa; James P Luyendyk
Journal:  Toxicology       Date:  2016-12-31       Impact factor: 4.221

2.  Antibody binding and inhibition of pyruvate dehydrogenase (PDH) in sera from patients with primary biliary cirrhosis.

Authors:  U Sundin
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.